⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of DevaCell, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
DevaCell, Inc.
↗San Diego, USA
DevaCell is a biotechnology company focused on developing next-generation, synthetic vector-based therapeutics using its proprietary ONCoat™ platform technology. The company aims to revolutionize patient care by creating therapies that can be systemically delivered and repeatedly administered, targeting indications such as oncology, vaccines, and gene therapy/gene editing.
The company's core innovation, the Designer Encapsulated Viral Assembly (DEVA), allows for the creation of nanolayers around viral surfaces. This technology is designed to prevent viral neutralization by the immune system, thereby enabling repeat administration and improving the safety and efficacy of oncolytic virus therapies and other gene-based treatments.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2012
Ownership:private
Status:operating
FUNDING
Stage:Pre-IPO
PIPELINE
Stage:Preclinical
Lead Drug Stage:Preclinical
Modalities:Oncolytic virus, Gene therapy, Vaccine
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
COMPETITION
Position:Emerging
Competitors:Onconano Medicine, SomaNautix, Ionic Pharmaceuticals, ExonanoRNA
LEADERSHIP
Key Executives:
David Pyrce - CEO
Jeff Sturgis - COO
Inanç Ortaç - CSO, Co-founder
Scientific Founders:Inanç Ortaç
Board Members:Larry G. Stambaugh, Inanç Ortaç, David Pyrce, Jennifer Cayer, Gala Yayla
LINKS
Website:devacell.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with DevaCell, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.